 |
|
|
| |
Curing Decompensated Wait-Listed HCV Patients with the New DAAs: Potential Significant Impact on Liver Transplant Wait List and Organ Allocation
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
S Munoz, R Reich, K Rothstein, G Xiao, V Patel, G McNulty, A Riera, S Guy
Hahnemann University Hospital, Drexel College of Medicine
Philadelphia, Pennsylvania
The 5 studies evaluated various combinations of polymerase and replication complex inhibitors including: the first 4 studies are clinical trials part of drug development programs by the corresponding pharmaceutical sponsors. We also included observational study of the English Expanded Access program, presented by Dr. Foster at the last EASL, because it focused on decompensated cirrhotics, had robust sample size, met our inclusion crietria, and brought the unique perpective of a real world study of DAA in decompensated cirrhotics.
Please note that none of the above antiviral combinations have been specifically approved by the FDA for use in decompensated cirrhosis. On the other hand, our own society AASLD and the IDSA recommendations indicate that decompensated cirrhotics can be treated with 3 of the above combinations..
|
| |
|
|
|
|
|
